Phaseline

Companies › AOTI

AOTI: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Cardiovascular; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Topical Wound Oxygen Therapy (TWO2)
Cyclical topical oxygen pressure applied directly to wound site in sealed environment
–Phase 4Venous Leg Ulcer (VLU)Jun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06754735Topical Wound Oxygen Therapy (TWO2)Phase 4Venous Leg Ulcer (VLU)CardiovascularJun 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Cell Biopeutics Resources Sdn Bhd TR Therapeutics Kerecis Beijing Inno Medicine Nectero Medical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.